中英文介绍丨艾美捷人LR3胰岛素样生长因子-I

Human LR3IGF-I is more potent than IGF-I in vitro ａnd in vivo. This increased potency is due to reduced binding of LR3IGF-I to most of the IGF binding proteins which modify the biological actions of IGF-I.

Human LR3IGF-I binds to the type 1 IGF receptor with similar affinity to wild type IGF-I.LR3

IGF-I was developed by GroPep specifically for supplementation of mammalian cell culture to support the survival ａnd proliferation of cells. It is engineered to have a higher biological potency than native IGF-I or IGF-II ａnd has several advantages over recombinant insulin. Supplementation of cell cultures with LR3IGF-I at a much lower concentration results in equivalent or better productivity than supplementation with standard concentrations of insulin. LR3IGF-I is better able to stimulate the type I IGF receptor ａnd thus induce a higher level of activation of intracellular signalling molecules which are responsible for promoting cell survival by inhibition of apoptosis.

Media grade LR3IGF-I is a high quality product for use in commercial cell culture.It can also be used as a research reagent at an economical cost to enable studies where higher quantities of peptide are required.

References Francis GL et al (1992) Journal of Molecular Endocrinology 8, 213-223

Yandell C et al (2004) Bioprocess International 2, 56-64

Source: Produced in E.coli.

Molecular Weight: 9110.6 ± 2 Daltons

Purity: ≥ 95 % (by SDS gel electrophoresis)

HPLC analysis: Three peaks with main peak being > 50% of total area

(Other species are micro heterogeneous forms which have biological activity)

N-terminal sequence: Analysis of 18 residues

Biological Activity: Proliferation of Chinese Hamster Ovary (CHO) cells

(EC50 ≤ 10 ng/ml)

Endotoxin: ≤ 0.1 EU/µg

Appearance: White powder freeze-dried from 0.1M acetic acid ａnd stored under

nitrogen at a slight vacuum.

Storage/Stability: At least 2 years at 2-8°C (as a freeze dried product).

Reconstitution: Handling of GroPep IGF-I, IGF-II ａnd IGF analogues

艾美捷LR3胰岛素样生长因子-I#GRO-AM001是IGF-I的83个氨基酸的类似物，其包含在位置3用精氨酸取代谷氨酰胺的完整人IGF-I序列，加上在N-末端的13个氨基酸的延伸肽。

人类LR3 IGF-I在体外和体内都比IGF-I更有效。这种效力的提高是由于LR3的结合IGF-I与大多数改变IGF-I生物作用的IGF结合蛋白结合。

人类LR3 IGF-I以与野生型IGF-I相似的亲和力与1型IGF受体结合。LR3型IGF-I由GroPep开发，门用于补充哺乳动物细胞培养物支持细胞的存活和增殖。它被设计成具有比天然IGF-I或IGF-II，并且与重组胰岛素相比具有几个优点。细胞的补充含有LR3的培养物IGF-I在低得多的浓度下产生与补充标准浓度的胰岛素。LR3型IGF-I能够更好地刺激I IGF受体，从而诱导更高水平的细胞内信号分子激活负责通过抑制细胞凋亡来促进细胞存活。

LR3胰岛素样生长因子-I详细信息：

来源：产自大肠杆菌。

分子量：9110.6±2道尔顿

纯度：≥95%（SDS凝胶电泳）

HPLC分析：三个峰，主峰面积大于总面积的50%

（其他物种是具有生物活性的微异质形式）

N端序列：18个残基的分析

生物活性：中国仓鼠卵巢（CHO）细胞的增殖

（EC50≤10 ng/ml）

内毒素：≤0.1 EU/µg

外观：从0.1M乙酸中冷冻干燥的白色粉末，在

在轻微真空下的氮气。

储存/稳定性：在2-8°C下至少保存2年（作为冷冻干燥产品）。

重组：GroPep IGF-I、IGF-II和IGF类似物的处理

LR3胰岛素样生长因子-I相关研究：

人LR3IGF-I（受体）

人[Arg3]IGF-I（介质）

人LR3IGF-I ELISA

人IGF-I（介质）

文献参考：

Francis GL et al (1992) Journal of Molecular Endocrinology 8, 213-223 Yandell C et al (2004) Bioprocess International 2, 56-64  

来源：https://www.amyjet.com/featured/mtdna-target.shtml